Publications Database

Accordino R. E. et al. (2016)

Psychopharmacological interventions in autism spectrum disorder.

Expert Opinion on Pharmacotherapy

May, 17(7), pp. 937-952.

Read Abstract (New Window)

Almeida D. M. et al. (2013)

Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report.

Pancreas

January, 42(1), pp. 177-118.

Read Abstract (New Window)

Aman M. G. et al. (1995)

Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use.

Journal of the American Academy of Child and Adolescent Psychiatry

34(12), pp. 1672-1681

Read Abstract (New Window)

Aman M. G. , Hollway J. A. , Arnold L. E. (2008)

Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.

Child and Adolescent Psychiatric Clinics of North America

17(4), pp. 713-738

Read Abstract (New Window)

Anagnostou E. et al. (2006)

Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder.

Journal of Clinical Psychopharmacology

26(4), pp. 444-446

Bachmann C. J. et al. (2013)

Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany.

Research in Developmental Disabilities

June, 34(9), pp. 2551-2563.

Read Abstract (New Window)

Baribeau D. A. , Anagnostou E. (2014)

An update on medication management of behavioral disorders in autism.

Current Psychiatry Reports

16(3), pp. 437

Read Abstract (New Window)

Belsito K. M. et al. (2001)

Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial.

Journal of Autism and Developmental Disorders

31(2), pp. 175-181

Read Abstract (New Window)

Benvenuto A. et al. (2013)

Pharmacotherapy of autism spectrum disorder.

Brain and Development

35(2), pp. 119-127.

Read Abstract (New Window)

Bird P. D. (2015)

The treatment of autism with low-dose phenytoin: a case report.

Journal of Medical Case Reports

9(1), p. 8.

Read Abstract (New Window)

Bitton J. Y. et al. (2015)

Does treatment have an impact on incidence and risk factors for autism spectrum disorders in children with infantile spasms?

Epilepsia

June, 56(6), pp. 856-863.

Read Abstract (New Window)

Brasić J. R. (1997)

Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid.

Psychology Report

80(1), pp. 163-170

Read Abstract (New Window)

Britton J. W. (2002)

Antiepileptic drug withdrawal: Literature review.

Mayo Clinic Proceedings

77(12), pp. 1378-1388

Read Abstract (New Window)

Camacho A. et al. (2012)

Levetiracetam-induced reversible autistic regression.

Pediatric Neurology

47(1), pp. 65-67.

Read Abstract (New Window)

Canitano R. (2005)

Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders.

Brain and Development

27(3), pp, 228-232

Read Abstract (New Window)

Canitano R. (2015)

Mood stabilizers in children and adolescents with autism spectrum disorders.

Clinical Neuropharmacology

September, 38(5), pp. 177-182.

Read Abstract (New Window)

Canitano R. , Scandurra V. (2011)

Psychopharmacology in autism: An update.

Progress in Neuro-Psychopharmacology and Biological Psychiatry

35(1), pp. 18-28.

Read Abstract (New Window)

Chadwick D. , MRC Antiepileptic Drug Withdrawal Study Group (1999)

Does withdrawal of different antiepileptic drugs have different effects on seizure recurrence? Further results from the MRC Antiepileptic Drug Withdrawal Study.

Brain

122(3), pp. 441-448

Read Abstract (New Window) Read Full (New Window)

Childs J. , Blair J. (1997)

Valproic acid treatment of epilepsy in autistic twins.

Journal of Neurosciece Nursing

29(4), pp. 244-248

Read Abstract (New Window)

Coskun M. , Bozkurt H. , Zoroglu S. (2009)

Possible lamotrigine-induced mania in a child with autism spectrum disorder and epilepsy.

Journal of Clinical Psychopharmacology

29(5), pp. 508-509